BCL2 and cancer: Here, we performed a targeted sequencing panel of 324 cancer‐related genes (including ABL1, BCL2, CDH1, EGFR, etc.)at an average depth of 500× in all the specimens to identify mutations in genes that may be pivotal for synchronous primary cancer (BioProject accession number: PRJNA761143).